Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2025, with a report date of September 22, 2025. The document serves as a transaction notification detailing share purchases by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). It does not contain operational updates or general business context beyond the specific transactions listed.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Transaction Date: September 19, 2025
- Ordinary Shares (London): Purchased at £15.0300 per share.
- American Depositary Shares (New York): Purchased at $40.7387 per ADS.
Material Changes
No material changes to the company's financial position or operations are reported. The filing exclusively documents the following insider purchases executed on September 19, 2025:
- Wendy Becker (Independent Non-Executive Director): Purchased 526 Ordinary Shares on the London Stock Exchange.
- Elizabeth (Liz) McKee Anderson (Independent Non-Executive Director): Purchased 240 ADSs on the New York Stock Exchange.
- Charles Bancroft (Senior Independent Non-Executive Director): Purchased 1,880 ADSs on the New York Stock Exchange.
- Dr. Hal Barron (Non-Executive Director): Purchased 240 ADSs on the New York Stock Exchange.
- Dr. Anne Beal (Independent Non-Executive Director): Purchased 240 ADSs on the New York Stock Exchange.
- Dr. Hal Dietz (Independent Non-Executive Director): Purchased 240 ADSs on the New York Stock Exchange.
- Dr. Jeannie Lee (Independent Non-Executive Director): Purchased 239 ADSs on the New York Stock Exchange.
- Dr. Vishal Sikka (Independent Non-Executive Director): Purchased 827 ADSs on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share purchases.
Investor Verification Checklist
- Verify the total number of shares purchased by the board of directors on September 19, 2025, to assess insider confidence.
- Confirm the exchange rates between GBP and USD on the transaction date to compare the value of purchases across London and New York markets.
- Check subsequent filings to determine if these purchases were part of a broader compensation plan or discretionary investment.
- Note that this filing contains no data on GSK's quarterly or annual financial performance; refer to Form 20-F for those metrics.